AstraZeneca PLC - Form 6-K Filing

This Form 6-K filing reports the US FDA approval of AstraZeneca PLC's Breztri Aerosphere for the maintenance treatment of asthma in patients 12 years of age and older. This marks the second indication for Breztri, which is already approved for COPD. The approval is based on the positive outcomes of the KALOS and LOGOS Phase III trials, which demonstrated significant clinical benefits of Breztri compared to dual-therapy inhalers. The drug, a single-inhaler triple therapy combining an inhaled corticosteroid/long-acting beta2-agonist with a long-acting muscarinic antagonist, showed a rapid onset of action and improved lung function. This approval is significant given that a large number of asthma patients remain uncontrolled on existing dual therapies. AstraZeneca is pursuing regulatory filings for Breztri in asthma in other major regions, including the EU, Japan, and China.